KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Other EventsItem 8.01 Other Events
On January24, 2018, Kura Oncology, Inc. (the “Company”) sold 3,136,722 shares of its common stock during intraday trading at a weighted average price per share of $18.85 for gross proceeds of approximately $59.1million. The shares were sold to the Company’s sales agreement with Cowen and Company, LLC (“Cowen”) dated January27, 2017, as amended on November9, 2017. Following these sales, the Company may offer and sell additional shares of its common stock having an aggregate offering price of up to $40.7million from time to time through Cowen to the sales agreement.
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
